Myriad Genetics Current Financial Leverage
| MYGN Stock | USD 18.51 0.13 0.70% |
Myriad Genetics holds a debt-to-equity ratio of 0.106. At this time, Myriad Genetics' Net Debt is very stable compared to the past year. As of the 19th of April 2024, Short Term Debt is likely to grow to about 31.7 M, while Short and Long Term Debt Total is likely to drop about 115.6 M. Myriad Genetics' financial risk is the risk to Myriad Genetics stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Myriad Genetics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Myriad Genetics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Myriad Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Myriad Genetics' stakeholders.
For most companies, including Myriad Genetics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Myriad Genetics the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 2.2434 | Book Value 8.712 | Operating Margin (0.13) | Profit Margin (0.35) | Return On Assets (0.07) |
Myriad |
Myriad Genetics Financial Leverage Rating
Myriad Genetics bond ratings play a critical role in determining how much Myriad Genetics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Myriad Genetics' borrowing costs.| Piotroski F Score | 3 Frail |
| Beneish M Score | -3.02 Unlikely Manipulator |
Myriad Genetics Debt to Cash Allocation
As Myriad Genetics follows its natural business cycle, the capital allocation decisions will not magically go away. Myriad Genetics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 145 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Myriad Genetics has a current ratio of 3.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Myriad Genetics until it has trouble settling it off, either with new capital or with free cash flow. So, Myriad Genetics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Myriad Genetics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Myriad to invest in growth at high rates of return. When we think about Myriad Genetics' use of debt, we should always consider it together with cash and equity.Myriad Genetics Total Assets Over Time
Myriad Genetics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Myriad Genetics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Myriad Genetics, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a a Myriad Genetics debt ratio should be compared their industry average or other competing firms.Myriad Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Myriad Genetics Use of Financial Leverage
Myriad Genetics financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Myriad Genetics's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Myriad Genetics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Myriad Genetics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Myriad Genetics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Myriad Genetics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 166.8 M | 115.6 M | |
| Net Debt | 101.3 M | 106.4 M | |
| Short Term Debt | 16.2 M | 31.7 M | |
| Long Term Debt | 258.1 M | 271 M | |
| Long Term Debt Total | 258.1 M | 155.7 M | |
| Short and Long Term Debt | 8.4 M | 8 M | |
| Net Debt To EBITDA | (1.49) | (1.42) | |
| Debt To Equity | 0.15 | 0.1 | |
| Interest Debt Per Share | 1.65 | 1.26 | |
| Debt To Assets | 0.11 | 0.07 | |
| Long Term Debt To Capitalization | 0.12 | 0.08 | |
| Total Debt To Capitalization | 0.13 | 0.08 | |
| Debt Equity Ratio | 0.15 | 0.1 | |
| Debt Ratio | 0.11 | 0.07 | |
| Cash Flow To Debt Ratio | (0.66) | (0.63) |
Myriad Genetics Investors Sentiment
The influence of Myriad Genetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Myriad. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Myriad Genetics' public news can be used to forecast risks associated with an investment in Myriad. The trend in average sentiment can be used to explain how an investor holding Myriad can time the market purely based on public headlines and social activities around Myriad Genetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Myriad Genetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Myriad Genetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Myriad Genetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Myriad Genetics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Myriad Genetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Myriad Genetics' short interest history, or implied volatility extrapolated from Myriad Genetics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Myriad Genetics Fundamentals Over Time. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.Note that the Myriad Genetics information on this page should be used as a complementary analysis to other Myriad Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Myriad Stock analysis
When running Myriad Genetics' price analysis, check to measure Myriad Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myriad Genetics is operating at the current time. Most of Myriad Genetics' value examination focuses on studying past and present price action to predict the probability of Myriad Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Myriad Genetics' price. Additionally, you may evaluate how the addition of Myriad Genetics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Myriad Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.18) | Revenue Per Share 9.097 | Quarterly Revenue Growth 0.106 | Return On Assets (0.07) | Return On Equity (0.32) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.